DESCRIPTION: 50 mg/mL Multi-dose Vial – Sterile
COMPARE TO: N/A
SIZE: 100 mL
UNIT OF SALE: 1
ORANGE BOOK: N/A
STORAGE: Exposure to pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from
freezing. It is recommended that the product be stored at 20-25°C (68-77°F), however, brief excursions
are permitted between 15-30°C (59-86°F).
Pentobarbital sodium Nembutal are nonselective central nervous system depressants which are primarily used as sedative hypnotics and also anticonvulsants in sub hypnotic doses. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances
The sodium salts of amobarbital, pentobarbital, phenobarbital, and secobarbital are available as sterile parenteral solutions.
Barbiturates are substituted pyrimidine derivatives in which the basic structure common to these drugs is barbituric acid, a substance which has no central nervous system (CNS) activity. CNS activity is obtained by substituting alkyl, alkenyl, or aryl groups on the pyrimidine ring.
NEMBUTAL Sodium Solution (pentobarbital sodium injection) is a sterile solution for intravenous or intramuscular injection. Each mL contains pentobarbital sodium 50 mg, in a vehicle of propylene glycol, 40%, alcohol, 10% and water for injection, to volume. The pH is adjusted to approximately 9.5 with hydrochloric acid and/or sodium hydroxide.
NEMBUTAL Sodium is a short-acting barbiturate, chemically designated as sodium 5-ethyl-5-(1-methyl butyl) barbiturate. The structural formula for pentobarbital sodium is:
The sodium salt occurs as a white, slightly bitter powder which is freely soluble in water and alcohol but practically insoluble in benzene and ether.
Buy Nembutal Pentobarbital Sodium
Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia.
Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis.
Barbiturate-induced sleep differs from physiological sleep. Sleep laboratory studies have demonstrated that barbiturates reduce the amount of time spent in the rapid eye movement (REM) phase of sleep or dreaming stage. Also, Stages III and IV sleep are decreased. Following abrupt cessation of barbiturates used regularly, patients may experience markedly increased dreaming, nightmares, and/or insomnia. Therefore, withdrawal of a single therapeutic dose over 5 or 6 days has been recommended to lessen the REM rebound and disturbed sleep which contributes to drug withdrawal syndrome (for example, decrease the dose from 3 to 2 doses a day for 1 week)